Division of Vascular Surgery, School of Medicine, 14716University of Missouri, Columbia, MO, USA.
Department of Family and Community Medicine, School of Medicine, 14716University of Missouri, Columbia, MO, USA.
Vascular. 2021 Feb;29(1):61-68. doi: 10.1177/1708538120937955. Epub 2020 Jul 5.
The current study evaluated all-cause 30-day readmissions after carotid endarterectomy.
Patients undergoing carotid endarterectomy were selected from the Cerner Health Facts® database using ICD-9-CM procedure codes from their index admission. Readmission within 30 days of discharge was determined. Chi-square analysis determined characteristics of the index admission (demographics, diagnoses, postoperative medications, and laboratory results) associated with readmission. Multivariate logistic regression models were used to identify characteristics independently associated with readmission.
In total, 5257 patients undergoing elective carotid endarterectomy were identified. Readmission within 30 days was 3.1%. After multivariable adjustment, readmission was associated with end-stage renal disease (OR: 3.21, 95% CI: 1.01-10.2), hemorrhage or hematoma (OR: 2.34, 95% CI: 1.15-4.77), procedural complications (OR: 3.07, 95% CI: 1.24-7.57), use of bronchodilators (OR: 1.48, 95% CI: 1.03-2.11), increased Charlson index scores (OR: 1.22, 95% CI: 1.08-1.38), and electrolyte abnormalities (hyponatremia < 135 mEq/L (OR: 1.69, 95% CI: 1.07-2.67) and hypokalemia less than 3.7 mEq/L (OR: 2.26, 95% CI: 1.03-4.98)).
Factors associated with readmission following carotid endarterectomy included younger age, increased comorbidity burden, end-stage renal disease, electrolyte disorders, the use of bronchodilators, and complications including bleeding (hemorrhage or hematoma). Of note, in this real-world study, only 40% of the patients received protamine, despite evidence-based literature demonstrating the reduced risk of bleeding complications. As healthcare moves towards quality of care-driven reimbursement, physician modifiable targets such as protamine utilization to reduce bleeding are greatly needed to reduce readmission, and failure to reduce preventable physician-driven complications after carotid interventions may be associated with decreased reimbursement.
本研究评估了颈动脉内膜切除术(CEA)后的全因 30 天再入院情况。
本研究使用 Cerner Health Facts®数据库中的 ICD-9-CM 手术代码,从指数入院中选择接受颈动脉内膜切除术的患者。确定出院后 30 天内的再入院情况。卡方分析确定了与再入院相关的指数入院特征(人口统计学、诊断、术后药物和实验室结果)。多变量逻辑回归模型用于确定与再入院独立相关的特征。
共确定了 5257 例接受择期颈动脉内膜切除术的患者。30 天内再入院率为 3.1%。多变量调整后,再入院与终末期肾病(OR:3.21,95%CI:1.01-10.2)、出血或血肿(OR:2.34,95%CI:1.15-4.77)、手术并发症(OR:3.07,95%CI:1.24-7.57)、使用支气管扩张剂(OR:1.48,95%CI:1.03-2.11)、Charlson 指数评分增加(OR:1.22,95%CI:1.08-1.38)和电解质异常(低钠血症 <135 mEq/L(OR:1.69,95%CI:1.07-2.67)和低钾血症 <3.7 mEq/L(OR:2.26,95%CI:1.03-4.98))有关。
颈动脉内膜切除术再入院的相关因素包括年龄较小、合并症负担增加、终末期肾病、电解质紊乱、使用支气管扩张剂以及出血(出血或血肿)等并发症。值得注意的是,在这项真实世界的研究中,尽管有循证文献表明使用鱼精蛋白可降低出血并发症的风险,但只有 40%的患者使用了鱼精蛋白。随着医疗保健向以质量为导向的报销转变,非常需要可由医生修改的目标,例如使用鱼精蛋白以减少出血,从而降低再入院率,而颈动脉介入后未能减少可预防的医生驱动的并发症可能会导致报销减少。